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http://dx.doi.org/10.1016/j.stemcr.2016.03.009SUMMARYPreviously we reported that nestin-positive human mesenchymal stromal cells (MSCs) derived from the olfactory mucosa (OM)
enhanced CNS myelination in vitro to a greater extent than bone-marrow-derived MSCs (BM-MSCs). miRNA-based fingerprinting re-
vealed the two MSCs were 64% homologous, with 26 miRNAs differentially expressed. We focused on miR-146a-5p and miR-140-5p
due to their reported role in the regulation of chemokine production and myelination. The lower expression of miR-140-5p in OM-
MSCs correlated with higher secretion of CXCL12 compared with BM-MSCs. Addition of CXCL12 and its pharmacological inhibitors
to neural co-cultures supported these data. Studies on related miR-146a-5p targets demonstrated that OM-MSCs had lower levels of
Toll-like receptors and secreted less pro-inflammatory cytokines, IL-6, IL-8, and CCL2. OM-MSCs polarized microglia to an anti-inflam-
matory phenotype, illustrating potential differences in their inflammatory response. Nestin-positive OM-MSCs could therefore offer a
cell transplantation alternative for CNS repair, should these biological behaviors be translated in vivo.INTRODUCTION
Bone-marrow-derived mesenchymal stromal cells (BM-
MSCs) have been reported to secrete neurotrophic cyto-
kines as well as a range of pro-inflammatory cytokines,
chemokines, and other soluble growth factors (Nakano
et al., 2010; Ma et al., 2013). Because of these properties,
their feasibility and safety of administration were assessed
in clinical trials for the treatment of multiple sclerosis
(MS), with results suggesting they can modulate the im-
mune response, protect neurons from degeneration, and
improve disease progression (Bonab et al., 2012; Connick
et al., 2012). MSCs have been isolated from a range of tis-
sues including bone marrow, adipose, pancreas, skin,
muscle, tendon, umbilical cord, skin, and dental pulp
(Hass et al., 2011; Wang et al., 2013). We have recently
isolated MSCs from the lamina propria of human olfac-
tory mucosa (OM) (termed OM-MSCs; Lindsay et al.,
2013); a tissue of fundamental interest in the context of
neuroprotection and repair because of its ability to
continually support neurogenesis throughout life (Grazia-
dei and Monti Graziadei, 1985). Our previous studies have
demonstrated that OM-MSCs have a similar antigenic
profile and differentiation properties to BM-MSCs (Lind-
say et al., 2013). However, the entire OM-MSC population
expressed nestin, while conversely around 50% of BM-
MSCs were nestin-positive, despite being isolated using
identical methodology (Johnstone et al., 2015). Impor-
tantly, there was a major difference in the ability ofStem Cell Reports j Vol. 6 j 729–742 j
This is an open access article under the COM-MSCs to promote CNS myelination in vitro via a
secreted factor(s) (Lindsay et al., 2013).
Since these properties can be explained by a vast number
of genes, we decided to use a microRNA (miRNA) array
approach to identify differences and similarities between
the twoMSCs.miRNAs are an abundantly expressed family
of small post-transcriptional regulators (18–24 nucleo-
tides). They control gene expression by modulating the
translation (usually by repression), stability, and localiza-
tion of specific mRNA targets (Ambros, 2001). They regu-
late numerous functions ranging from cell differentiation,
proliferation, and apoptosis to fat metabolism (Skalnikova
et al., 2011). miRNAs are thought to act as regulatory sig-
nals for maintaining stemness, self-renewal, and differenti-
ation in adult stem cells and are therefore important in
controlling classic stem cell properties (Collino et al.,
2011; Tome´ et al., 2011). Characterization of miRNAs
from MSCs of different tissue sources could be relevant
not only as a marker of the cell but also to fully understand
their biological activities and give an insight into what
makes them different (Collino et al., 2011). Recent work
has described nestin-positive MSCs as a subpopulation
(Tondreau et al., 2004; Wiese et al., 2004) that originates
not from the mesoderm but from the neural crest giving
nestin-positive MSCs specialized niche functions over nes-
tin-negative MSCs (Isern and Me´ndez-Ferrer, 2011; Isern
et al., 2014). Therefore, in this investigation, we have
compared the miRNA profile of nestin-positive OM-MSCs
with classical BM-MSCs to determine any importantMay 10, 2016 j ª 2016 International Society for Stem Cell Research 729
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biological differences that, in particular, may be relevant to
their role in cell transplantation therapies for the treatment
of demyelinating conditions, such as MS.RESULTS
miRNA Analysis of OM-MSCs and BM-MSCs
Analysis revealed 195 mature miRNAs detected in OM-
MSCs (n = 4 patient samples) and BM-MSCs (n = 4 patient
samples), of which 125 were equivalently expressed (EE).
This demonstrates 64% identity, despite being isolated
from different tissues; moreover, 27 of these EE miRNAs
have already been reported for BM-MSCs (Gao et al.,
2011; Figure 1A). These data suggest that MSCs derived
from OM express a similar core set of miRNAs compared
with BM.
In contrast, 26 were differentially expressed (DE) across
all samples, with 16 being downregulated in OM-relative
to BM-MSCs (Figure 1B). These miRNAs have over 300 tar-
gets, therefore a contextual approachwas adoptedwhereby
miRNAs associatedwithMSCbiologywere identified. Since
our previous comparative studies identified differences in
cell proliferation, cell survival, and myelination (Lindsay
et al., 2013), we focused on miR-140-5p and miR-146a-5p
(Figure 1B), which have already been identified as key reg-
ulators of these processes (Suzuki et al., 2010; Go¨ttle et al.,
2010).qPCR Analysis for miR-140-5p and miR-146a-5p
qPCR confirmed a significant 3.01-fold higher expression
of miR-140-5p in BM-MSCs compared with OM-MSCs
(n = 4 patient samples for both, p < 0.05; Figures 1C and
1E), and a significant 7.99-fold higher expression of miR-
146a-5p in OM-compared with BM-MSCs (n = 4 patient
samples for both, p < 0.05; Figures 1D and 1E), confirming
the miRNA analysis.Cytokine/Chemokine Analysis
GeneGo MetaCore analysis revealing high-confidence
mRNA targets for miR-140-5p suggested SDF-1 (referred to
as CXCL12 hereafter) secretion may be differentially regu-
lated between the MSCs. Multiplex analysis of the condi-
tioned media (CM) collected from OM- and BM-MSCs
was performed with fibroblast (FB) and CD271-FT-CM
used as comparisons (CM derived from n = 4 patient sam-
ples). Since we have previously shown that both FB-CM
and CD271-FT-CM do not promote myelination (Lindsay
et al., 2013), these were considered an appropriate compar-
ison to ensure secreted factors were specifically generated
from OM-MSCs (see Table 1); 13 were not detected and
nine were secreted to equivalent levels across all groups
(CCL1, CCL2, CCL3, CCL8, CX3CL1, G-CSF, CXCL10,730 Stem Cell Reports j Vol. 6 j 729–742 j May 10, 2016SCF, and VEGF). CCL11 was significantly higher within
both OM-MSC-CM and CD271-FT-CM compared with
BM-MSC-CM and FB-CM (p < 0.05, all comparisons), sug-
gesting the expression of a tissue-specific chemokine rather
than MSC specific. CCL13 was significantly lower within
FB-CM compared with all other cell type CM (p < 0.05,
all comparisons), however, it was equivalently expressed
within OM-MSCs, BM-MSCs, and CD271-FT-CM. CCL5
was markedly increased in CD271-FT-CM (p < 0.01).
CXCL12 was the only cytokine present in significantly
greater quantities in OM-MSC-CM compared with either
BM-MSC-CM (p < 0.01), CD271-FT-CM (p < 0.01), or FB-
CM (p < 0.05, Figure 2A). In addition, the neurotrophic fac-
tors BDNF, NT3, NT4/5, and NGF were assayed in BM- and
OM-MSC-CM (n = 3 patient samples for both). NT3was un-
detectable, and both cell types secreted equivalent low
levels of BDNF (OM-MSC-CM, 19.2 ± 5.3 pg/ml; BM-
MSC-CM, 11.9 ± 4.83 pg/ml) and NT4/5 (OM-MSC-CM,
21.9 ± 0.3 pg/ml; BM-MSC-CM, 20.0 ± 0.7 pg/ml). OM-
MSC-CM contained significantly higher levels of NGF
(33.8 ± 6.8 pg/ml) compared with BM-MSC-CM (1.2 ±
0.6 pg/ml).
Transfection of Cells with miR-140-5p Inhibitor and
Mimic Affects Production of CXCL12 mRNA
OM- and BM-MSCs (n = 3, patient samples for both) were
transfected with miR-140-5p antagomir or mimic, a
random sequence miRNA molecule (scrambled control)
or dH2O (Figures 2B and 2C) to confirm their ability to
modulate miR-140-5p expression. MiR-140-5p antagomir
silenced expression, while the mimic significantly upregu-
lated miR-140-5p in both OM- and BM-MSCs. These data
confirm that levels of miR-140-5p can be modulated by
both the antagomir and mimic.
To validate direct correlation ofmiR-140-5p and CXCL12
expression, bothMSC types were transfected with themiR-
140-5p antagomir or mimic, and CXCL12 mRNA levels
were quantified (Figures 2D and 2E). The mimic resulted
in virtually undetectable levels of CXCL12 in both MSC
types. Antagomir induced a significant increase in BM-
MSCs compared with control levels (p < 0.05; Figure 2E),
and although the levels of CXCL12 mRNA were increased
in OM-MSCs compared with the mimic, they were still
below that of control OM-MSCs (Figure 2D), which inher-
ently expressed higher levels of CXCL12 mRNA than BM-
MSCs. This confirms that increased levels of miR-140-5p
negatively regulate the expression of CXCL12.
CXCL12 Promotes In Vitro CNS MyelinationWhich Is
Inhibited Using the Neutralizing Antibody and
Receptor Blocker to CXCL12
Our previous data suggest that OM-MSCs promoted
in vitro CNS myelination via a secreted factor. Here
Figure 1. miRNA Profiling of OM-MSCs and BM-MSCs
(A) Twenty-seven equivocally expressed (EE) miRNAs in OM-MSCs (n = 4 patient samples) and BM-MSCs (n = 4 patient samples) that
associate specifically with MSCs (significance determined at PFDR < 0.05 rejects the null hypothesis and concludes that they are EE).
(B) Twenty-six differentially expressed (DE) miRNAs between both cell types. Table shows the fold change (FC) in expression of BM-MSCs
versus OM-MSCs (n = 4 patient samples, significance at PFDR < 0.05 and an FCR 1.5). TwomiRNAs of interest, hsa-miR-140-5p and hsa-miR-
146a-5p, are highlighted in red.
(C) qPCR confirms miR-140-5p is significantly upregulated in BM-MSCs compared with OM-MSCs (n = 4 patient samples, mean ± SEM,
*p < 0.05 determined by one-way ANOVA, Tukey’s multiple comparison).
(D) qPCR confirms miR-146-5p is upregulated in OM-MSCs compared with BM-MSCs (n = 4 patient samples, mean ± SEM, *p < 0.05,
determined by one-way ANOVA, Tukey’s multiple comparison).
(E) FC in expression of miR-140-5p and miR-146-5p in OM-MSCs versus BM-MSCs.we provide evidence that CXCL12 could be this fac-
tor. Myelinating CNS co-cultures were treated with
CXCL12 (100 ng/ml), CXCL12 receptor CXCR4 blocker
(AMD3100), OM-MSC-CM, as well as OM-MSC-CM treated
with a neutralizing antibody to CXCL12 or AMD3100
(n = 4, all treatments and four different patient samples;
Figures 3A and 3B). Media containing the CXCL12
neutralizing antibody or AMD3100 were used as controls.Exogenous CXCL12 significantly increased myelination
almost 2-fold compared with controls (p < 0.05), which
was blocked by AMD3100. The pro-myelinating effect of
OM-MSC-CM (p < 0.05) was also reduced by AMD3100
and when treated with the neutralizing antibody to
CXCL12. These data indicate that CXCL12 is at least
partially responsible for the pro-myelinating effect of
OM-MSCs.Stem Cell Reports j Vol. 6 j 729–742 j May 10, 2016 731
Table 1. Multiplex Chemokine Analysis of CM Showing the
Comparative Differences in Secreted Cytokines
Cytokine Significant Difference
CXCL12 **<OM only
CCL1 NS
CCL2 NS
CCL3 NS
CCL8 NS
CX3CL1 NS
G-CSF NS
CXCL10 NS
SCF NS
VEGF NS
CCL11 *<OM
*<CD271-FT
CCL13 *>FB
CCL5 **<CD271-FT
NS, not significantly different; *<OM, *<CD271-FT, represents that the
cytokine was secreted in significantly higher amounts in CM from OM-
MSCs and CD271-FTl *>FB, represents it was present in significantly less
amounts in fibroblasts (FB), **<CD271-FT or significantly higher in
CD271-FT-CM. CXCL12 was the only chemokine secreted at significantly
higher amounts in OM-MSC-CM compared with all other cell types (*p <
0.05, **p < 0.01, n = 3 for all, as determined by one-way ANOVA, Tukey’s
multiple comparison).Transfection with miR-140-5p Antagomir or Mimic
Can Affect In Vitro CNS Myelination
We next determined if modulating miR-140-5p in OM- or
BM-MSCs can affect myelination in vitro. BM-MSC-CM
was collected from cells transfected with the miR-140-5p
antagomir and added to cultures (n = 6 patient samples; Fig-
ures 3C and 3D). Antagomir-transfected BM-MSC-CM
significantly increased myelination by 1.64 ± 0.19-fold
compared with control (n = 6 patient samples, p < 0.05)
or that induced by control transfections (n = 6 patient sam-
ples, p < 0.01 for both). The increased myelination was
brought back to levels that were not significant from con-
trol by the addition of either the antibody to CXCL12 or
AMD3100 (n = 3 patient samples for both). CM derived
from BM-MSCs transfected with miR-140-5p mimic (n = 3
patient samples) showed no increase in myelination from
control. OM-MSC-CM collected from cells treated with
miR-140-5p antagomir increased myelination compared
with controls (p < 0.05) but was not significantly different
to that produced by control transfections (n = 6, patient
samples; Figures 3C and 3E). The pro-myelinating effect732 Stem Cell Reports j Vol. 6 j 729–742 j May 10, 2016of CM collected from antagomir-treated OM-MSCs could
be reduced in the presence of either the antibody to
CXCL12 or AMD3100 (n = 3 patient samples for both).
OM-MSC-CM collected from miR-140-5p mimic-treated
cells reduced myelination to control. This confirms that
miR-140-5p can induce OM- and BM-MSCs to increase
CXCL12 secretion, which is pro-myelinating, since block-
ing its activity abolishes the effect.
CXCR4 Expression on Oligodendrocyte Precursor
Cells and Microglia
CXCL12 is known to mediate its effect via CXCR4 and
CXCR7, therefore cellular expression may help determine
the mode of action. Oligodendrocyte precursor cells
(OPCs) and microglia were both found to express CXCR4,
however no expression was found on astrocytes (n = 3, all
cell types; Figures 4A and 4B). Western blotting of
CXCR4 revealed OPCs (n = 6) and microglia (n = 4) to
have at least three distinct isoforms, however, both had dif-
ferential expression of each (Figures 4B and 4C). It was
found that the most abundant isoform expressed within
microglia was the 50 kDa isoform, while OPCs were found
to predominantly have the 45 kDa isoform. Total protein
quantification of all CXCR4 isoforms was found not to
be significantly different between microglia (1.72 ±
0.31 a.u.) versus OPCs (1.33 ± 0.35 a.u.). CXCR7 expression
was only barely detectable by western blot and not immu-
nocytochemistry on both OPCs and microglia (Figure 4B).
Therefore the pro-myelinating capabilities of CXCL12
could be mediated via its action on OPCs or microglia, or
both. Purified OPCs were treated with CXCL12, OM-, or
BM-MSC-CM (from three different patient samples for
both) and labeled with markers of OPC differentiation
(n = 3; Figure 4D). There were no differences in immu-
noreactivity of NG2 (early OPC marker), O4 (middle/late
OPC marker), or PLP (late myelinating OPC marker). How-
ever, CXCL12 significantly changed OPC morphological
appearance from a predominantly simple (bipolar) to a
more complex (multi-branched) morphology, similar to
that foundwithOM- or BM-MSC-CM treatment (Figure 4E;
p < 0.001). OM-MSC-CM resulted in significantly more
OPCs exhibiting a membranous morphology when com-
pared with either control or BM-MSC-CM (p < 0.001 for
both), and although the result of OM-MSC-CM treatment
looked to be greater, it was not significantly different to
CXCL12 treatment. Overall this suggests that CXCL12
can mediate morphological OPC differentiation via its
direct action on the OPC itself. This hypothesis was
confirmed by examining the effect of CXCL12, OM-, and
BM-MSC-CM on purified OPCs incubated with inert nano-
fibers (Figure 4F). In these experiments, PLP-positive OPCs
had significantly greater cell areas ensheathing axons in
both CXCL12 and OM-MSC-CM compared with controls
Figure 2. MiR-140-5p Regulates CXCL12
in OM-MSCs
(A) CXCL12 quantification in OM-MSC-CM,
BM-MSC-CM, CD271-FT-CM, and fibroblast
(FB)-CM. CXCL12 levels were significantly
higher in OM-MSC-CM compared with all
other cell types (n = 4 patient samples,
mean ± SEM, *p < 0.05 determined by one-
way ANOVA, Tukey’s multiple comparison).
(B and C) qPCR analysis of OM- and BM-MSCs
transfected with miR-140-5p antagomir or
mimic, a scrambled control, and dH2O only.
MiR-140-5p expression was significantly
greater in the mimic compared with controls
(n = 3 patient samples, mean ± SEM, ***p <
0.001, one-way ANOVA, Tukey’s multiple
comparison). BM-MSCs transfected with the
mimic significantly increased levels from
control (n = 3 patient samples, mean ± SEM,
*p < 0.05, one-way ANOVA, Tukey’s multiple
comparison).
(D) OM-MSC transfection with the miR-140-
5p mimic caused significantly lower levels of
CXCL12 mRNA compared with controls (n = 3
patient samples, mean ± SEM, *p < 0.05,
one-way ANOVA, Tukey’s multiple compari-
son).
(E) Antagomir induced a significant in-
crease in CXCL12 mRNA in BM-MSCs
compared with control levels (n = 3 patient
samples, mean ± SEM, *p < 0.05, one-way
ANOVA, Tukey’s multiple comparison).(n = 3 each treatment and patient samples). BM-MSC-CM
also caused an increase in PLP-positive cell area, however
this was foundnot to be significantly different fromcontrol
due to the variability among samples (n = 3 patient sam-
ples). This suggests that both CXCL12 and OM-MSC-CM
promoted process extension and wrapping in the absence
of axonal signals to a greater extent than BM-MSC-CM.
Microglia are thought to polarize into distinct pheno-
types, pro-inflammatory (depicted by iNOS expression) or
anti-inflammatory (increased arginase I expression). To
determine if the microglia phenotype plays a role in medi-
ating myelination, we treated purifiedmicroglia with OM-,
BM-MSC-CM (n = 4 patient samples for both), or CXCL12(n = 4). CM fromboth cell types were tested for endogenous
endotoxin levels (Pierce Endotoxin Quantification Kit;
Thermo Scientific) to rule out any difference as a result of
CM contamination prior to use. Lipopolysaccharide (LPS)
and IL-4 were used as controls to induce the pro- and
anti-inflammatory phenotype, respectively (Figures 4G
and 4H). LPS stimulation shifted microglia predominantly
to the pro-inflammatory phenotype assessed by increased
iNOS expression compared with control (n = 4, p < 0.01),
while IL-4-treated microglia expressed arginase I with no
iNOS detectable (n = 4), suggesting a population that is
similar to control. Treatment of microglia with OM-MSC-
CM and CXCL12 increased arginase I expression comparedStem Cell Reports j Vol. 6 j 729–742 j May 10, 2016 733
Figure 3. CXCL12 Promotes In Vitro CNS Myelination which is Regulated by miR-140-5p
(A) Co-cultures stained for myelin (green PLP) and axons (red SMI-31) treated with OM-MSC-CM, OM-MSC-CM in the presence of antibody to
CXCL12 (OM-MSC-CM + anti-CXCL12), or CXCR4 blocker (OM-MSC-CM + AMD3100), CXCL12 (100 ng/ml), or CXCL12 in the presence of
AMD3100. Scale bar represents 100 mm.
(legend continued on next page)
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with the control (p < 0.001 and p < 0.05, respectively) with
no detectable iNOS expression, suggesting a larger shift to
the anti-inflammatory phenotype in both conditions.
BM-MSC-CM did not stimulate a significant increase in
arginase I levels from control but did however lead to
increased iNOS production (p < 0.01), the only treatment
besides LPS to do so (Figures 4G and 4H). This would
strongly suggest that OM-MSC-CM and CXCL12 cause mi-
croglia to polarize predominantly to an anti-inflammatory
phenotype, in contrast to BM-MSC-CM, which appears to
shift them more toward a pro-inflammatory phenotype.
Recently, the anti-inflammatory phenotype of microglia
has been reported to play a role in myelination through
the production of activin A (Miron et al., 2013). Therefore
we assessed activin A levels within the CM of microglia
treated with CXCL12 (n = 3) or OM- or BM-MSC-CM
(n = 3 patient samples for both) with their respective CM
used as controls (Figure 4I). It was found that there were
no identifiable increases in activin A in CXCL12-treated
cultures, and although OM- and BM-MSC-CM showed
increased levels, this was similar to that already present
within the CM alone. Therefore, both types of MSC, but
not microglia, secrete activin A.
MiR-146a-5p Network and Chemokine Regulation
The GeneGo MetaCore network for miR-146a-5p indi-
cated an association with Toll-like receptor (TLR) expres-
sion and the regulation of inflammatory chemokines.
This suggests differential modulation of the inflammatory
response, which is an important consideration for cell
transplant-mediated repair. Total TLR2 and 4 levels were
significantly less in OM-MSCs compared with BM-MSCs
(n = 6 patient samples for both, p < 0.01 and p < 0.05,
respectively; Figure 5A). There was notably less TLR2
expression in both cell types compared with their TLR4
expression since only TLR4 was present abundantly
enough to be detected via fluorescence-activated cell sort-
ing (FACS) (n = 3 patient samples for both; Figure 5B).
MiR-146a-5p is thought to modulate the secretion of(B) CXCL12 and OM-MSC-CM increased myelination significantly comp
blocker and anti-CXCL12 abolished the pro-myelinating effect of OM-M
patient samples, mean ± SEM, *p < 0.05, one-way ANOVA, Tukey’s m
(C) Representative images of co-cultures stained for myelin (green P
transfected with miRNA control, antagomir (140-5p Antag), or miR-14
of anti-CXCL12 (140-5p + Ab) or the blocker (140-5p + AMD3100). Sc
(D) CM from BM-MSCs treated with miR-140-5p antagomir led to a sign
samples for all). The antagomir-induced increase could be reduced to
(n = 3 patient samples for both). CM from BM-MSCs induced by the m
(E) OM-MSC-CM collected after miR-140-5p mimic transfection sig
transfection with antagomir had no effect (n = 3 patient samples). In
Tukey’s multiple comparison.
Dotted horizontal lines demarcate control levels, vertical dotted lineIL-6 and IL-8, and BM-MSC-CM was found to contain at
least 1.5-fold more of both these and CCL2 than OM-
MSC-CM (Figure 5C). Quantification was carried out by
ELISA (n = 3 patient samples for both, p < 0.01, p <
0.001, and p < 0.05; Figure 5D).
The miR-146a-5p antagomir (Figure 6A) caused a signif-
icant reduction inmiR-146a-5p miRNA levels in OM-MSCs
(p < 0.05), however BM-MSCs, which have less of this
miRNA constitutively, showed a non-significant reduction
(n = 3, patient samples for both). The levels of IL-8, IL-6,
and CCL2 were all assessed before and after LPS stimula-
tion for 24 hr in CM collected from BM-MSCs, OM-
MSCs, OM-MSC transfected with dH2O or with a
scrambled control, or with the miR-146-5p antagomir
(n = 4 all treatments and n = 4 patient samples for both;
Figures 6B–6D). Both control transfections expressed
similar non-significant levels of cytokine expression before
and after stimulation with LPS, therefore only dH2O-trans-
fected OM-MSC control data are presented. The higher
secretion of IL-8, IL-6, and CCL2 within BM-MSC-CM
in basal conditions compared with OM-MSC-CM was
confirmed (p < 0.05, p < 0.01, p < 0.05, respectively). LPS
caused IL-8 to increase to equivalent levels within OM-
MSC-CM and BM-MSC-CM. However, OM-MSCs in the
presence of the miR-146a-5p antagomir produced a signif-
icantly larger increase in LPS-stimulated IL-8 levels
(p < 0.05), suggesting that repression of miR-146a-5p led
to increased production of IL-8. IL-6 levels were found to
be lower in OM-MSC-CM both before and after LPS stimu-
lation when compared with BM-MSC-CM (p < 0.01 and
p < 0.001, respectively). Transfection with miR-146a-5p
antagomir caused an increase in the LPS-induced levels
of IL-6 in OM-MSCs (p < 0.05). CCL2 levels, although
lower in OM-MSCs compared with BM-MSCs under basal
conditions (p < 0.05), was found not to be significantly
different after LPS stimulation in antagomir-treated OM-
MSCs (Figure 6D). These data provide evidence that miR-
146-5p can regulate the secretion of both IL-6 and IL-8
but not CCL2 in both OM- and BM-MSCs.ared with control levels (demarcated by the dotted line). AMD3100
SC-CM and CXCL12 but did not affect myelination on their own (n = 4
ultiple comparison).
LP) and axons (red SMI-31) treated with CM from BM- or OM-MSCs
0-5p mimic and miR-140-5p antagomir-derived CM in the presence
ale bar represents 100 mm.
ificant increase in myelination compared with control (n = 6 patient
control levels in the presence of anti-CXCL12 or AMD3100 blocker
iR-140-5p mimic also did not promote myelination.
nificantly reduced the pro-myelinating effect of OM-MSCs while
(D) and (E), mean ± SEM, *p < 0.05, **p < 0.01, one-way ANOVA,
s detail experimental comparisons made to control.
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Figure 4. CXCL12 Action May Be via OPC Process Extension and Microglial Polarization
(A) CXCR4 expression (green) in oligodendrocytes (OPCs, red O4), microglia (MG) and astrocytes (GFAP, red). White arrows show microglia
positive for CXCR4. Scale bar represents 50 mm.
(B) CXCR4 and CXCR7 protein levels in microglia (MG) and OPCs (n = 2, both cell types). GAPDH used as loading control.
(C) Graphical representation of western blot analysis. Microglia and OPCs show differing expression of various CXCR4 kDa bands. MG
preferentially express the 50 kDa band (n = 4), while OPCs predominantly express the 45 kDa band (n = 6) (mean ± SEM, **p < 0.05, two-
way ANOVA, Sidak’s multiple comparison).
(D) OPC differentiation was quantified using markers for OPCs (NG2), oligodendrocytes (O4), and mature oligodendrocytes (PLP) after
CXCL12 treatment (n = 3), and CM from OM-MSCs (n = 3 patient samples) and BM-MSCs (n = 3 patient samples) compared with control (n = 3,
mean ± SEM). No difference in marker expression was found.
(E) Process extension of OPCs assessed by O4. OM-MSC-CM (OM-CM, n = 3 patient samples), BM-MSC-CM (BM-CM, n = 3 patient samples), and
CXCL12 treatment (n = 3) significantly increased the number of complex processes and reduced the number of simple processes formed
compared with control media. OM-MSC-CM caused a significant increase in membranous process formation (mean ± SEM, ***p < 0.001,
two-way ANOVA, Tukey’s multiple comparison).
(F) Quantification of the PLP-positive cell area of OPCs grown on inert nanofibers and treated with OM-MSC-CM (n = 3, patient samples),
BM-MSC-CM (n = 3, patient samples), or CXCL12 (n = 3). There was a significantly greater cell area in the presence of OM-CM and CXCL12
(mean ± SEM, *p < 0.05 one-way ANOVA, Tukey multiple comparisons). Example images of OPCs (red PLP, blue DAPI) incubated with inert
nanofibers. Scale bar represents 100 mm.
(legend continued on next page)
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Figure 5. MiR-146-5p Differentially Regulates TLR4, TLR2, and Cytokine Secretion
(A) Graphical representation of TLR4 and TLR2 (western blot shown as inserts) in BM-MSCs (n = 6 patient samples) and OM-MSCs (n = 6
patient samples). BM-MSCs have significantly higher levels compared with OM-MSCs (mean ± SEM, *p < 0.05, **p < 0.01, Students unpaired
t test).
(B) FACS analysis of TLR4 expression on OM- and BM-MSCs (n = 3, patient samples both).
(C) OM-MSC (n = 1 patient sample) and BM-MSC (n = 1 patient sample) cytokine profile. Insert shows dot plot while the graph illustrates the
mean pixel intensity of the blot. IL-6 (1) IL-8 (2), and CCL2 (3) were expressed 1.5-fold higher in BM-MSC-CM.
(D) ELISA analysis of IL-8, IL-6, and CCL2 in BM-MSC-CM (n = 3 patient samples) and OM-MSC-CM (n = 3 patient samples, mean ± SEM,
*p < 0.05, **p < 0.01, ***p < 0.001, Students unpaired t test).DISCUSSION
In this investigation, miRNA-based fingerprinting demon-
strated that OM- and BM-MSCs were 64% homologous,(G and H) Graphical representation of western blot analysis (H) of arg
MSCs (n = 4 patient samples) and BM-MSCs (n = 4 patient samples), L
significantly upregulated in LPS and BM-MSC-CM (BM-CM) treatment.
OM-MSC-CM (OM-CM) (mean ± SEM *p < 0.05, **p < 0.01, ***p < 0.0
(I) Quantification of activin A in microglia media after stimulation w
and BM-MSC-CM (BM-MSC-MG, n = 3 patient samples) for 24 hr. OM
(mean ± SEM).suggesting they have related regulatory miRNA patterns.
Others have shown thatMSCs derived from different tissue
niches share expression of a core set of miRNAs that regu-
late associated target genes, although miRNA similarityinase I and iNOS after treatment with CXCL12 (n = 4), CM from OM-
PS (n = 4), IL-4 (n = 4), and control treatments (n = 4). iNOS was
Arginase I levels were significantly upregulated in both CXCL12 and
01, one-way ANOVA, Tukey’s multiple comparison).
ith CXCL12 (n = 3), OM-MSC-CM (OM-CM-MG, n = 3 patient samples)
-MSC-CM (OM-CM) and BM-MSC-CM (BM-CM) were used as controls
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Figure 6. Regulation of IL-6 and IL-8 by
miR-146a-5p
(A) qPCR of miR-146a-5p levels in OM-MSCs
(n = 3 patient samples) and BM-MSCs (n = 3
patient samples) after transduction with
antagomir. There was a significant reduc-
tion within OM-MSCs (mean ± SEM, *p <
0.05, one-way ANOVA with Tukey’s multiple
comparison).
(B–D) Quantification of IL-8 (B), IL-6 (C),
and CCL2 (D) in OM-MSC-CM (OM-MSCs, n = 4
patient samples) and BM-MSC-CM (BM-MSCs,
n = 4 patient samples) before and after LPS
treatment (Untransfected), and OM-MSCs
after transfection with the antagomir
to miR-146a-5p (Antagomir Transfected).
(B) OM-MSCs secrete less IL-8 compared
with BM-MSCs. LPS stimulation of OM-MSCs
caused an increase in IL-8 levels, which was
significantly greater in the presence of
the antagomir (mean ± SEM, *p < 0.05, one-
way ANOVA, Tukey’s multiple comparison).
(C) IL-6 levels were significantly less in OM-
MSCs compared with BM-MSCs both before
and after LPS stimulation. IL-6 could be
induced by LPS to greater levels in the
presence of the antagomir (mean ± SEM,
*p < 0.05, **p < 0.01, ***p<0.001, one-
way ANOVA, Tukey’s multiple comparison).
(D) CCL2 was secreted significantly less in
OM-MSC-CM compared with BM-MSC-CM.
There were no differences before or after LPS
stimulation or in the presence of the anta-
gomir (mean ± SEM, *p < 0.05, one-way
ANOVA, Tukey’s multiple comparison).between the two MSC types here was greater than that re-
ported for otherMSCs (Lazzarini et al., 2014).We identified
26 DE miRNAs, which could explain their different biolog-
ical properties. We focused on miRNAs associated with
chemokine production and myelination. and therefore
examined miR-146a-5p, and miR-140-5p in more detail
due to their reported association (Nicolas et al., 2008;
Suzuki et al., 2010; Go¨ttle et al., 2010; Hsieh et al., 2013).
MiR-140-5p (downregulated in OM-MSCs) has been re-
ported to inhibit the expression of CXCL12 (Nicolas
et al., 2008), which has been shown to promote oligoden-
droglial cell maturation in vitro (Go¨ttle et al., 2010; Kadi
et al., 2006) and myelination in the demyelinated cupri-
zone model (Patel et al., 2012). Given that miR-140-5p is
downregulated in OM-MSCs, it was possible that CXCL12
expression correlated with their increased myelinating
capabilities. We demonstrated that OM-MSCs secreted
significantly greater amounts of CXCL12, confirmed its
pro-myelinating effect using myelinating co-cultures, and
using miR-140-5p mimic/antagomir, we demonstrated an738 Stem Cell Reports j Vol. 6 j 729–742 j May 10, 2016inverse relationship of mRNA for secreted CXCL12. More-
over, CM from MSCs transduced with the miR-140-5p
antagomir and mimic affected CNS myelination in vitro,
indicating that the pro-myelinating effect of OM-MSCs
was due, at least in part, to CXCL12 secretion controlled
by miR-140-5p. This reveals an important role for MSC-
secreted CXCL12 in myelination. It is well understood
that CXCL12 is vital in controlling hematopoietic stem
cell and progenitor function within the human and rodent
BM (Isern et al., 2014; Greenbaum et al., 2013) and that
there are certain cell types that secrete high levels of
CXCL12: CXCL12-abundant reticular (CAR) cells, nestin-
GFP + stromal cells, and leptin receptor + stromal cells.
However, what is not known currently is whether CD271
selection isolates which cell population from the BM,
although a recent report has demonstrated nestin gene
expression after CD271 purification (Li et al., 2014). Since
we have previously shown our BM-MSCs to be only 50%
nestin positive, it would suggest we are harvesting only
some of the nestin-positive cells previously shown to
secrete CXCL12 (Isern et al., 2014; Greenbaum et al., 2013).
CD271may also isolate a population that does not produce
CXCL12 or produces it in only low amounts, unlike in the
OM where it exclusively isolates the nestin-positive MSCs.
However, a direct correlation between nestin, CD271
expression, and CXCL12 secretion has yet to be established
in OM-MSCs.
To elucidate CXCL12 mechanism of action, we deter-
mined the cellular expression of its receptors (Lipfert
et al., 2013). Both OPCs and microglia strongly expressed
multiple isoforms of CXCR4, which may reflect various
post-transcriptional modifications that have been shown
to exist previously (Sloane et al., 2005; Carlisle et al.,
2009). CXCR7 expression could be detected only weakly,
suggesting that the predominant receptor type is CXCR4.
OPCs responded to CXCL12 by enhanced process branch-
ing and membrane formation, however myelin marker
differentiation remained unchanged. Since a prominent
activity for chemokines is to regulate leukocyte trafficking,
which is considered to occur through actin cytoskeleton
modulation (Thelen and Stein, 2008), it could be that
CXCL12 regulates OPC actin cytoskeleton during process
extension in myelination.
Since microglia express CXCR4, it is possible that
CXCL12 may indirectly influence myelination through
their activity. Microglia are both a source and/or target for
CXCL12 (Albright et al., 1999; Lee et al., 2002), which pro-
motes their migration and proliferation. Microglia treated
with CXCL12 or OM-, not BM-MSC-CM, upregulated argi-
nase I expression, which resembles polarization seen in
anti-inflammatory macrophages (Murray et al., 2014).
Conversely, iNOS expression was induced by BM-MSC-
CM but not CXCL12 or OM-MSC-CM. These differences
suggest that OM-MSCs induce microglia to polarize pre-
dominantly to a more anti-inflammatory phenotype, in
contrast to BM-MSC-CM, which appears to shift them
toward a pro-inflammatory phenotype. Although the
anti-inflammatory phenotype is thought to play a role in
myelination via activin A (Miron et al., 2013), there was
no difference in activin A levels in CM of both MSCs or
an upregulation of it in treated microglia, suggesting that
this is not the mechanism.
Further studies were carried out on miR-146a-5p, which
is thought to be a mediator of inflammation, and a regu-
lator of IL-6 and IL-8 and the expression of the immune re-
ceptors TLR2 and 4 (Taganov et al., 2006). TLRs are present
on a range of non-immune cells, and a number (predomi-
nantly TLR2 and TLR4) can be stimulated by endogenous
ligands termed damage-associated molecular patterns.
Hence the role they play in the pathophysiology of cell
transplantation is important (Leventhal and Schro¨ppel,
2012). Stimulation of TLRs on MSCs by endogenous li-
gands released during inflammation and cellular stresshas been linked to the perpetuation of chronic inflamma-
tory responses after transplantation (DelaRosa and Lom-
bardo, 2010). Therefore, one could postulate that
transplanted cells that have fewer TLRs present would
induce a lower inflammatory response.
The pro-inflammatory cytokines IL-6, IL-8, and CCL2
were constitutively secreted in greater levels in BM-MSC-
CM compared with OM-MSC-CM, although LPS-treated
OM-MSCs only had reduced levels of IL-6. Since LPS stim-
ulation in the presence of miR-146a-5p antagomir resulted
in significantly greater levels of IL-6 and IL-8 secreted by
OM-MSCs, this corroborates the inhibitory role of miR-
146a-5p in regulating their secretion. It should be noted,
however, that the levels were not higher than those consti-
tutively secreted by BM-MSCs. So while miR-146a-5p anta-
gomir transfection has shown modest effects after LPS
stimulation, it may not be enough to upregulate the secre-
tion of IL-6 and IL-8 to high levels. This is presumably since
these two cytokines are predicted to be targeted by 18 and
30 other miRNAs, respectively, which may have a regula-
tory role. CCL2, which is not thought to be on the same
miR-axis, was not upregulated with antagomir treatment,
suggesting that this miRNA was specific for the regulation
of IL-6 and IL-8. Moreover, it is tempting to speculate
that the induction of the pro-inflammatory phenotype of
microglia by BM-MSC-CM is due to their differing cytokine
secretion.
With increasing evidence that nestin-positive MSCs that
reside in the bone marrow are from the neural crest and a
subpopulation that secrete CXCL12 (Isern et al., 2014), it
is possible that OM-MSCs are an enriched population of
these neural-crest-derived MSCs. Equally, as BM-MSCs are
a heterogeneous population, it is plausible that purifying
the nestin-positive cells may result in enhancing their
CNS repair potential to similar levels as OM-MSCs. Given
our findings and that OM-MSCs are an easily accessible
source of cells; we propose that they may be an alternative
cellular source for cell-transplant-mediated CNS repair.EXPERIMENTAL PROCEDURES
Cell Culture
Culture of Human Olfactory Mucosa MSCs
Biopsy samples were obtained with Central Office for Research
Ethics Committees (COREC, REC reference 07/S0710/24) ethical
approval and informed patient consent from the uppermiddle tur-
binates in 21 patients undergoing nasal septoplasty surgery, aged
between 26 and 93 years (average age, 55.0 ± 3.4 years; Table S1).
They were purified using CD271 (Quirici et al., 2002) and grown
as previously described (Lindsay et al., 2013). Purification using
CD271 selection allowsMSCs to be specifically selected from fibro-
blasts and other adherent populations. Before use, cells were as-
sessed for MSC surface antigens and myelinating potential asStem Cell Reports j Vol. 6 j 729–742 j May 10, 2016 739
described previously (Lindsay et al., 2013). Purified cells were
termed OM-MSCs while flow-through (FT) cells were retained
and termed CD271-negative FT cells (CD271-FT). FT cells do not
bind CD271 and are thus a contaminating cell population.
CD271-FT were used to ensure secreted factors were specifically
generated from the purified MSCs.
Culture of Human Bone Marrow MSCs
BM aspirates were obtained with ethical approval and informed
patient consent from iliac crests of 18 patients undergoing hip
replacement aged 33 to 86 years (average age, 63.9 ± 3.1 years;
Table S1). BM collected in DMEM containing 5% fetal bovine
serum (FBS), 0.5% heparin, 0.1% EDTA was layered onto
Histopaque-1077 then centrifuged at 400 3 g. After washes (PBS,
5% FBS, and 0.1% EDTA), the pellet was resuspended in 10%
aMEM and plated on collagen-coated (10 mg/ml; Sigma-Aldrich)
25 cm2 tissue culture flasks. MSCs were isolated by standard plastic
adherence and, upon confluency, were purified similar to OM-
MSCs using the EasySep Human MSC CD271 Positive Selection
Kit (STEMCELL Technologies) so that direct comparisons could
be made. Cells were assessed for expression of MSC surface anti-
gens and myelinating potential prior to use (Lindsay et al., 2013).
Collection of Conditioned Media
CM was collected from flasks of different donor patients of OM-
MSCs, BM-MSCs, CD271-FT, or human dermal fibroblasts (HDF;
Supplemental Experimental Procedures) at P2-P4. For OPC, micro-
glia, and chemokine experiments, CM was collected in DMEM
modified by Bottenstein and Sato (1979) (DMEM-BS). For myeli-
nating culture experiments, CM was collected in DM (Lindsay
et al., 2013). After 72 hr, the CM was collected and used immedi-
ately or stored at 20C. Cell counts after collection ensured no
significant differences in cell number between flasks.
Culture of Rat Microglia and Oligodendrocyte Precursor Cells
Sprague Dawley cortices were digested and grown in DMEM
containing 10% FBS with 4.5 g/l glucose, L-glutamine, pyruvate,
and 1% penicillin/streptomycin (DMEM-10%) using standard
methods (Noble and Murray, 1984). After 7–10 days, microglia
and OPCs were purified by differential attachment (Miron et al.,
2013). See Supplemental Experimental Procedures for details.
Myelinating Spinal Cord Rat Cultures
Myelinating spinal cord co-cultures were set up using standard
methods (Sørensen et al., 2008). After 12 days, insulin was
withdrawn and cultures treated until day 28 by the addition of
OM- or BM-MSC-CM diluted 1:2 with DM, CXCL12 (100 ng/ml;
Peprotech), anti-CXCL12 (10 mg/ml; R&D Systems), and CXCR4
antagonist, AMD3100 (50 mM; Sigma). AMD3100 was added for
1 hr prior to feeding to allow binding. In antagomir/mimic exper-
iments, CM from transfected BM- or OM-MSCs was added at day
12 or pre-treated with anti-CXCL12 before addition. Information
on quantification of myelination can be found in Supplemental
Experimental Procedures.Microarray Analysis
RNA Isolation
RNA from four donors of OM-MSCs (n = 4) and BM-MSCs (n = 4)
grown to P4 was prepared using an Exiqon miRCURY RNA Kit.
Absorbance ratios were determined as indicators of sample yield
and purity. RNA quality control was performed using the Agilent740 Stem Cell Reports j Vol. 6 j 729–742 j May 10, 20162100 Bioanalyser and the RNA 6000 Nano Kit according to the
manufacturer’s instructions, to determine the RNA integrity num-
ber. Samples were analyzed on the Agilent miRNA platform
(Agilent’s SurePrint G3 Human v16microRNA 83 60Kmicroarray
slides; miRBase version 16.0). 100 ng of RNA was used as input for
each microarray.
Microarray
Eight individual microarrays, representing 1,349 miRNAs, 1,205
human (1,199 verified as realmiRNAs inmiRbase 18), and 144 viral
were used. The accession number for the microarray reported in
this paper is ArrayExpress: E-MTAB-4594. Methods are found in
Supplemental Experimental Procedures.Antagomir, Mimic, and miRNA Transfection
BM- and OM-MSCs were transfected using Attractene Fast-
Forward (Qiagen). Twelve-well plates were seeded with 1 3 105
cells/well and 50 nM mirVana miRNA miR-140-5p inhibitor
(Ambion,MH10205) andmimic (MC10205),mi-146a-5p inhibitor
(MH10722) and mimic (MC10205), miRNA negative (scrambled)
control (RNU58A) or dH2O (no miRNA control) was added in trip-
licate. Plates were incubated at 37C for 24 hr, then cells were lysed
for mRNA, or the media replaced with DM for 48 hr for CM collec-
tion, which was used to treat myelinating cultures.qPCR
RNA content was analyzed using Nanondrop 1000 (Thermo Scien-
tific) and cDNA synthesized usingQuantiTect reverse transcription
(Qiagen). qRT-PCRwas performed using SYBRMasterMix (Qiagen)
by StepOnePlus Real-Time PCR (Applied Biosystems) in triplicate.
Log CT values were calculated and plotted against concentration
to produce a standard curve from which each sample was extrapo-
lated. For primers, see Supplemental Experimental Procedures.Chemokine Assays
Multiplex Cytokine/Chemokine Assay
CM from BM-, OM-MSCs, HDF, and CD271-FT (n = 4, in triplicate)
were analyzed using Milliplex human cytokine/chemokine mag-
netic 23 bead panel II (Millipore; HCP2MAG-62K-PX23) run on
the Bio-Rad Bio-Plex with Luminex 200 and Human Chemokine
Array Kit (Invitrogen; LHC6003) following the manufacturer’s
protocol.
ELISA
IL-8, IL-6, and CCL2 ELISAMAXDeluxe kits (Biolegend) were used
according to the manufacturer’s protocol to assess OM- and BM-
MSC-CM before and after overnight LPS stimulation (10 ng/ml;
Sigma) or after miR-140-5p antagomir transduction as previously
described. Both the Human Multi-Neurotrophin Rapid Screening
ELISA Kit (Biosensis) and Human Activin A Kit (BD Bioscience)
were used as per the manufacturers’ protocols. All ELISA samples
were run in triplicate.Western Blot
Cells were lysed using CelLytic M (Sigma) containing protease in-
hibitor cocktail (Sigma) and protein concentration determined
(NanoDrop; Thermo Scientific). Samples were run using standard
methods described in Supplemental Experimental Procedures.
FACS Analysis
OM- and BM-MSCs were incubated with human receptor FC
block (eBioscience; 14-9161-71) for 20 min, followed by TLR4-
488 (eBioscience; 53-9917-41) or mouse isotype control 488
(eBioscience; 53-4724-80) for 20 min on ice. Cells were washed
then resuspended in PBS containing 2% paraformaldehyde and
evaluated by flow cytometry in an FACS Caliber (BD) and analyzed
using FlowJo.
Statistical Analysis
For each independent experiment, data were collected usingMSCs
generated fromat least three different patients. Donor-derived cells
were used up to passage four, limiting the number of experiments
that could be conducted from individual samples; thus multiple
MSC donors were required to complete all experiments. Table S2
details which biopsies were used for each experiment. Data are pre-
sented as the mean ± SEM and analyzed using Student’s t test,
ANOVA with Dunnett post-test, Sidak’s or Tukey’s adjustment for
multiple comparisons where appropriate, using Prism software
version 5.0 (GraphPad Software). Differences were considered sig-
nificant at p < 0.05.
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